Conditional Approval Granted To Cell Therapeutics' Pixuvri


The European Medicines Agency's Committee for Medicinal Products for Human Use granted a positive opinion for conditional approval for Cell Therapeutics Inc.'s (Nasdaq: CTIC) Pixuvri sending the stock price soaring 25 cent to $1.36. 


About this Entry

This page contains a single entry by published on February 17, 2012 9:06 AM.

Ultra Petroleum Falls Short was the previous entry in this blog.

Gilead Reports Disappointing Results is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12